A single-cell atlas of large B cell lymphomas reveals distinct malignant archetypes predictive of clinical outcomes.

Five conserved malignant B cell archetypes, including a quiescent memory B cell-like type, predict clinical outcomes in large B cell lymphomas, with Archetype 4 linked to poor survival.

• Why it matters: Heterogeneity in LBCLs causes variable treatment responses and high relapse rates, underscoring the need for better prognostic markers and personalized therapies.
• What they did: Single-cell RNA-seq, BCR-seq, and TCR-seq were performed on 63 LBCL biopsies, revealing five archetypes of malignant B cells that co-occur within tumors and vary among patients.
• The result: High levels of Archetype 4, marked by memory B cell features and quiescence, were associated with worse event-free survival, enabling improved patient stratification for targeted treatment.